MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

IBUPROFEN; METHOCARBAMOL

から入手可能:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATCコード:

M03BA53

INN（国際名）:

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

投薬量:

200MG; 500MG

医薬品形態:

TABLET

構図:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

OTC

治療領域:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

製品概要:

Active ingredient group (AIG) number: 0248961001; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2017-06-13

製品の特徴

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............